Why CBG and Other Rare Cannabinoids Will Supplant CBD – Nasdaq

Biomedican on Nasdaq

Biomedican on Nasdaq

In a recent article “Why CBG and Other Rare Cannabinoids Will Supplant CBD” published in Nasdaq, CEO and founder of Biomedican Max Makhieev featured the importance of highly popular rare cannabinoids that can dominate CBD. The cannabis market is projected to reach $146.4 billion by 2025 due to the rapidly growing demand for cannabinoids. Over one hundred known cannabinoids including the most well-known cannabinoids i.e CBD and THC and rare cannabinoids like CBG are available in the market. Powerful health benefits of rare cannabinoids increased their demand in the food and beverage, cosmetics, health, and pharmaceuticals industry.

CBG, also known as “The Mother of Cannabinoids“, enjoys the perks of being the most sought-after rare cannabinoid. Both CBG and its acidic form CBGA are precursors of all other cannabinoids. Versatile medical properties made CBG stand out from all other cannabinoids. Medical benefits of CBG include regrowth of brain cells, inhibition of cancer cell metastasis, appetite stimulation, and various neuroprotective benefits. CBG is near to replace CBD because CBG can be added as an ingredient in food and beverages without modification.

THCA, an acidic form of THC, lacks an intoxicating effect, unlike its parent compound THC that possesses a strong psychoactive effect. THCA can be used to treat arthritis, lupus, nausea, appetite loss, and prostate cancer due to its health benefits.

CBN is a well-known rare cannabinoid due to its anticonvulsant properties. It can regulate the immune system, aid sleep, and treat pain and inflammation.

THCV is considered an ideal compound for the treatment of bone disorders such as osteoporosis due to its ability to prevent bone degeneration and increase the growth of new bone cells.

Max Makhieev expects CBD to be replaced by more potent rare cannabinoids such as CBG, THCA, CBN, THCV, and others. According to Max Makhieev, “CBG will be at the forefront of cannabinoids boom”.

Biomedican is designing patented low-cost methods of growing high-value compounds at scale with proprietary yeasts. We invite investors to participate in the novel biosynthesis method developed by Biomedican to produce high-value compounds.


Saba IqbalAuthor posts

Saba Iqbal

Dr. Saba Iqbal is a contributing writer for BioMedican. She's a rocket pharmacist turned writer. Dr. Saba's education includes a doctoral degree in pharmacy (Pharm D) from the University of Sargodha, Pakistan. In search of a career that would take advantage of her medical and pharmaceutical skills, Dr. Saba found medical writing – a career path a few medical students consider. In her journey "from a medical bench to pen," she has worked with several startups for many years managing content on biotech products, pharmaceuticals, drugs, devices, and techniques. While keeping up with the latest trends in medical writing, she aims to use her writing skills to clearly communicate complex scientific, medical, and health information to the potential investor and general audience.

Leave a Reply

Your email address will not be published. Required fields are marked *